Likewise, trehalose treatment has been evidenced to stabilize aggregate-prone polyglutamine tracts, as exemplified by an engineered, repeat-containing myoglobin protein in vitro, and to reduce protein aggregates by oral treatment in vivo, thereby alleviating motor deficits and improving survival in a mouse model of Huntington’s disease [57]. The gene discussed is MB; the disease is Huntington disease.